BG
NERV icon

BlackRock Group’s Minerva Neurosciences NERV Stock Holding History

BlackRock Group’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$46K Buy
+495
New +$50.5K ﹤0.01% 2918

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock Group's NERV Position: Q4 2016 in Review

BlackRock Group opened a new position in Minerva Neurosciences (NERV) in Q4 2016: 495 shares worth $46K. The stake represents ﹤0.01% of the portfolio and ranks #2918 among its holdings.

78 funds tracked by Wall St. Rank hold NERV as of Q4 2016.

  • BlackRock Group held 495 shares of Minerva Neurosciences worth $46K as of Q4 2016.
  • Minerva Neurosciences was a new BlackRock Group position in Q4 2016.
  • Minerva Neurosciences made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2918 holding.
  • 78 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.